» Articles » PMID: 20005637

Radiosurgery for Craniopharyngioma

Overview
Specialties Oncology
Radiology
Date 2009 Dec 17
PMID 20005637
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To analyze the outcomes of gamma knife stereotactic radiosurgery (SRS) for residual or recurrent craniopharyngiomas and evaluate the factors that optimized the tumor control rates.

Methods And Materials: A total of 46 patients with craniopharyngiomas underwent 51 SRS procedures at University of Pittsburgh between 1988 and 2007. The median tumor volume was 1.0 cm(3) (range, 0.07-8.0). The median prescription dose delivered to the tumor margin was 13.0 Gy (range, 9-20). The median maximal dose was 26.0 Gy (range, 20-50). The mean follow-up time was 62.2 months (range, 12-232).

Results: The overall survival rate after SRS was 97.1% at 5 years. The 3- and 5-year progression-free survival rates (solid tumor control) were both 91.6%. The overall local control rate (for both solid tumor and cyst control) was 91%, 81%, and 68% at 1, 3, and 5 years, respectively. No patients with normal pituitary function developed hypopopituitarism after SRS. Two patients developed homonymous hemianopsia owing to tumor progression after SRS. Among the factors examined, complete radiosurgical coverage was a significant favorable prognostic factor.

Conclusion: SRS is a safe and effective minimally invasive option for the management of residual or recurrent craniopharyngiomas. Complete radiosurgical coverage of the tumor was associated with better tumor control.

Citing Articles

Radiosurgery versus radiation therapy for long term local control rate of craniopharyngioma: a meta-analysis.

Yoo H, Ham C, Roh H, Jo H, Kwon W, Yoon W Neurosurg Rev. 2025; 48(1):93.

PMID: 39873790 DOI: 10.1007/s10143-025-03238-1.


Controversies in neuro-oncology: Focal proton versus photon radiation therapy for adult brain tumors.

Eekers D, Zegers C, Ahmed K, Amelio D, Gupta T, Harrabi S Neurooncol Pract. 2024; 11(4):369-382.

PMID: 39006517 PMC: 11241386. DOI: 10.1093/nop/npae040.


Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy.

Ma J, Chen T, Zhang J, Cao W, Gao G, Yu X Clin Transl Oncol. 2024; 26(9):2198-2204.

PMID: 38488982 DOI: 10.1007/s12094-024-03435-2.


Should post-operative stereotactic radiosurgery be the standard of care in Craniopharyngioma patients?.

Gupta S, Agrawal D, Kedia S, Kale S World Neurosurg X. 2024; 22:100327.

PMID: 38455244 PMC: 10918274. DOI: 10.1016/j.wnsx.2024.100327.


Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.

Gritsch D, Santagata S, Brastianos P Curr Treat Options Oncol. 2024; 25(2):261-273.

PMID: 38300480 PMC: 11203386. DOI: 10.1007/s11864-023-01156-2.